Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. IMLYGIC IMLYGIC® (talimogene laherparepvec) has been genetically modified to replicate within tumors and to produce the immune stimulatory protein granulocyte-macrophage colony-stimulating factor (GM-CSF). When IMLYGIC® is injected into melanoma tumors, it causes lysis of tumor cells followed by release of tumor-derived antigens, which together with virally derived GM-CSF may promote an antitumor immune response. However, the exact mechanism of action is unknown ((https://www.imlygic.com/en/Mechanism-of-Action)). imlygic.txt Last modified: 2024/06/07 02:53by 127.0.0.1